These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19729622)

  • 1. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.
    Kean S
    Science; 2009 Sep; 325(5945):1188. PubMed ID: 19729622
    [No Abstract]   [Full Text] [Related]  

  • 2. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
    Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
    Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
    Metcalfe C; de Sauvage FJ
    Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog pathway inhibition and the race against tumor evolution.
    Atwood SX; Chang AL; Oro AE
    J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.
    Brinkhuizen T; Reinders MG; van Geel M; Hendriksen AJ; Paulussen AD; Winnepenninckx VJ; Keymeulen KB; Soetekouw PM; van Steensel MA; Mosterd K
    J Am Acad Dermatol; 2014 Nov; 71(5):1005-8. PubMed ID: 25199678
    [No Abstract]   [Full Text] [Related]  

  • 7. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
    Mohan SV; Chang AL
    Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
    Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
    Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with Hedgehog pathway inhibitors.
    Low JA; de Sauvage FJ
    J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Following the hedgehog to new cancer therapies.
    Dlugosz AA; Talpaz M
    N Engl J Med; 2009 Sep; 361(12):1202-5. PubMed ID: 19726764
    [No Abstract]   [Full Text] [Related]  

  • 11. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog drugs begin to show results.
    Garber K
    J Natl Cancer Inst; 2008 May; 100(10):692-7. PubMed ID: 18477794
    [No Abstract]   [Full Text] [Related]  

  • 14. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
    Kunstfeld R
    Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
    Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
    Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced treatment for basal cell carcinomas.
    Atwood SX; Whitson RJ; Oro AE
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
    Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
    Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing hedgehog for the treatment of basal cell carcinoma.
    Harms KL; Dlugosz AA
    JAMA Dermatol; 2013 May; 149(5):607-8. PubMed ID: 23677088
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
    Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
    Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.